SCHEMBL5307709

SCHEMBL5307709

CCN(CC)c1ccc(C(=O)c2cc(C#N)cc3ccc4cccn4c23)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 2/20 0.40
▸ L3MBTL1 Q9Y468 4/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ MAPT P10636 9/20 0.34
▸ MEN1 O00255 7/20 0.34
▸ KMT2A Q03164 7/20 0.34
▸ KDM4E B2RXH2 3/20 0.34
▸ GFER P55789 2/20 0.34
▸ ALDH1A1 P00352 7/20 0.32
▸ POLB P06746 3/20 0.32
▸ USP2 O75604 2/20 0.32
▸ LMNA P02545 2/20 0.32
▸ MAPK1 P28482 2/20 0.32
▸ RECQL P46063 1/20 0.32
▸ BLM P54132 1/20 0.32
▸ HPGD P15428 3/20 0.32
▸ SMN1; SMN2 Q16637 3/20 0.32
▸ ATM Q13315 2/20 0.32
▸ HSD17B10 Q99714 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5256708 0.89 ALDH1A1 (0.39) L3MBTL1NPC1RAB9AMAPTMEN1
SCHEMBL5959210 0.85 AKR1C3 (0.35) L3MBTL1NPC1MAPTMEN1KMT2A
SCHEMBL5257355 0.84 SLC22A12 (0.38) KDM4E
SCHEMBL5259338 0.84 ROCK2 (0.36) NPC1MEN1KMT2APOLB
SCHEMBL5310994 0.84 F2 (0.39) KDM4EALDH1A1HPGDATMPKM
SCHEMBL5959281 0.83 KMT2A (0.40) NPC1MAPTMEN1KMT2AKDM4E
SCHEMBL5313506 0.83 MAPK14 (0.42) MAPTMEN1KMT2AALDH1A1USP2
SCHEMBL5308588 0.83 MAPK14 (0.35) NPC1RAB9AMEN1KMT2A
SCHEMBL5959255 0.83 MAPT (0.41) L3MBTL1NPC1RAB9AMAPTMEN1
SCHEMBL5959229 0.82 PLAU (0.38) NPC1RAB9AMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135480-B2 Anticarcinogenic agents; colon, lymphoma, lung, prostate and breast cancers CYTOVIA, INC. (US) 2006-11-14 — — US claimed
US-20050014759-A1 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2005-01-20 — — US claimed
EP-1578424-A4 SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A| QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA INC (US) 2007-08-08 — — EP disclosed
US-7135480-B2 Anticarcinogenic agents; colon, lymphoma, lung, prostate and breast cancers CYTOVIA, INC. (US) 2006-11-14 — — US disclosed
EP-1578424-A2 SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A] QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS Cytovia, Inc. (US) 2005-09-28 — — EP disclosed
US-20050014759-A1 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2005-01-20 — — US disclosed
WO-2004055163-A2 SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO[1,2-A]QUINOLINES CYTOVIA, INC. (US) 2004-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014759-A1 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis CASP3, CASP7, CASP1 MAOB 3997/4885L3MBTL1 47/4885NPC1 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback